Document:

Exhibit 10.6

 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

This First Amendment to Employment Agreement (this
 “First Amendment”) is entered into as of December 22, 2021 (the “Amendment Effective Date”),
between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Christina Rossi (the “Executive”).
Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement (as defined below).

 

WHEREAS, the Company and the Executive are parties
to the Employment Agreement dated as of October 29, 2018 (the “Employment Agreement”); and

 

WHEREAS, the Company and the Executive desire to
amend the Employment Agreement as set forth below;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is amended as follows:

 

1.             Section 5(a) of
the Employment Agreement shall be amended and restated as follows:

 

“Sale Event. During the Term, if within
twelve (12) months after a Sale Event, the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or
the Executive terminates employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement
and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination,

 

(i)             the
Company shall pay the Executive a lump sum in cash in an amount equal to the sum of (A) one and one-half (1.5) times the Executive’s
current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Sale Event, if higher) plus (B) one
and one-half (1.5) times the Executive’s Target Incentive Compensation ((A) and (B) together, the “Change in Control
Payment”), provided any Change in Control Payment shall be less the Restrictive Covenants Agreement Setoff, if applicable; and

 

(ii)            if
the Executive was participating in the Company’s group health (medical, dental and/or vision) plan immediately prior to the Date
of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for eighteen (18)
months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution
that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

 

(iii)           all
time-based stock options and other time-based stock-based awards held by the Executive shall accelerate and become fully exercisable or
non-forfeitable as of the Date of Termination; provided that, if any stock options or other stock-based awards held by the Executive prior
to the Effective Date have accelerated vesting terms that are more favorable to the Executive than those set forth in this Section 5(a)(iii),
the vesting terms of those stock options or other stock-based awards shall apply as opposed to the accelerated vesting terms set forth
in this Section 5(a)(iii) solely with respect to such awards.

 

    - 1 -

     

    

 

The amounts payable under Section 5(a)(i) and (ii) shall
be paid or commence to be paid within 60 days after the Date of Termination; provided however, that if the 60-day period begins in one
calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the
last day of such 60-day period.”

 

2.            To
the extent that there is any inconsistency between the terms and conditions of this First Amendment and the terms and conditions of the
Employment Agreement, the terms and conditions of this First Amendment shall prevail.

 

3.            This
First Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original,
but such counterparts shall together constitute one and the same document. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission method, and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

4.             Except
as amended hereby, the Employment Agreement remains in full force and effect and, as amended hereby, the Employment Agreement represents
the entire agreement between the Executive and the Company, and there are no other agreements, written or oral, relating to the subject
matter hereof. On and after the First Amendment Effective Date, all references in the Employment Agreement to “this Agreement”
(including “hereof,” “herein” and similar words or phrases) shall mean the Employment Agreement, as amended by
this First Amendment.

 

IN WITNESS WHEREOF, the undersigned have executed
this First Amendment as of the Amendment Effective Date.

 

	 	BLUEPRINT MEDICINES CORPORATION
	 	 	 
	 	By:	/s/ Jeffrey W. Albers
	 	Name:	Jeffrey W. Albers
	 	Title:	President and Chief Executive Officer
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Christina Rossi
	 	Christina Rossi

 

    - 2 -Exhibit 10.7

 

FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT
AGREEMENT

 

This First Amendment to Amended and Restated Employment
Agreement (this “First Amendment”) is entered into as of December 22, 2021 (the “Amendment Effective
Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and L. Becker Hewes,
M.D. (the “Executive”). Capitalized terms used and not defined herein shall have the meanings ascribed to such terms
in the Employment Agreement (as defined below).

 

WHEREAS, the Company and the Executive are parties
to the Amended and Restated Employment Agreement dated as of January 11, 2021 (the “Employment Agreement”); and

 

WHEREAS, the Company and the Executive desire to
amend the Employment Agreement as set forth below;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is amended as follows:

 

1.             Section 5(a) of
the Employment Agreement shall be amended and restated as follows:

 

“Sale Event. During the Term, if during
the Protection Period, the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or
the Executive terminates employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement
and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination,

 

(i)            the
Company shall pay the Executive a lump sum in cash in an amount equal to the sum of (A) one and one-half (1.5) times the Executive’s
current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Sale Event, if higher) plus (B) one
and one-half (1.5) times the Executive’s Target Incentive Compensation ((A) and (B) together, the “Change in Control
Payment”), provided any Change in Control Payment shall be less the Restrictive Covenants Agreement Setoff, if applicable; and

 

(ii)           if
the Executive was participating in the Company’s group health (medical, dental and/or vision) plan immediately prior to the Date
of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for eighteen (18)
months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution
that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

 

(iii)          all
time-based stock options and other time-based stock-based awards held by the Executive shall accelerate and become fully exercisable or
non-forfeitable as of the Date of Termination; provided that, if any stock options or other stock-based awards held by the Executive prior
to the Effective Date have accelerated vesting terms that are more favorable to the Executive than those set forth in this Section 5(a)(iii),
the vesting terms of those stock options or other stock-based awards shall apply as opposed to the accelerated vesting terms set forth
in this Section 5(a)(iii) solely with respect to such awards.

 

    - 1 -

     

    

 

The amounts payable under Section 5(a)(i) and (ii) shall
be paid or commence to be paid within 60 days after the Date of Termination; provided however, that if the 60-day period begins in one
calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the
last day of such 60-day period.”

 

2.             To
the extent that there is any inconsistency between the terms and conditions of this First Amendment and the terms and conditions of the
Employment Agreement, the terms and conditions of this First Amendment shall prevail.

 

3.             This
First Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original,
but such counterparts shall together constitute one and the same document. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission method, and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

4.             Except
as amended hereby, the Employment Agreement remains in full force and effect and, as amended hereby, the Employment Agreement represents
the entire agreement between the Executive and the Company, and there are no other agreements, written or oral, relating to the subject
matter hereof. On and after the First Amendment Effective Date, all references in the Employment Agreement to “this Agreement”
(including “hereof,” “herein” and similar words or phrases) shall mean the Employment Agreement, as amended by
this First Amendment.

 

IN WITNESS WHEREOF, the undersigned have executed
this First Amendment as of the Amendment Effective Date.

 

	 	BLUEPRINT MEDICINES CORPORATION
	 	 	 
	 	By:	/s/ Jeffrey W. Albers
	 	Name:	Jeffrey W. Albers
	 	Title:	President and Chief Executive Officer
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ L. Becker Hewes
	 	L.
Becker Hewes, M.D.

 

    - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]